Boyd Watterson Asset Management LLC OH lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 26.6% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 4,160 shares of the medical research company’s stock after selling 1,511 shares during the period. Boyd Watterson Asset Management LLC OH’s holdings in Amgen were worth $716,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of New York Mellon Corp raised its position in shares of Amgen by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock valued at $1,403,676,000 after buying an additional 195,200 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Amgen by 1.6% during the first quarter. Schwab Charles Investment Management Inc. now owns 2,894,780 shares of the medical research company’s stock valued at $474,947,000 after buying an additional 45,403 shares during the last quarter. UBS Asset Management Americas Inc. raised its position in shares of Amgen by 3.1% during the first quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock valued at $446,250,000 after buying an additional 81,362 shares during the last quarter. Swiss National Bank raised its position in shares of Amgen by 26.5% during the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock valued at $432,490,000 after buying an additional 551,600 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in shares of Amgen by 0.7% during the first quarter. Ameriprise Financial Inc. now owns 1,479,687 shares of the medical research company’s stock valued at $242,555,000 after buying an additional 10,109 shares during the last quarter. 78.10% of the stock is owned by institutional investors and hedge funds.

Amgen Inc. (NASDAQ AMGN) traded down 0.55% during mid-day trading on Friday, hitting $185.82. 2,032,454 shares of the stock traded hands. The company has a 50 day moving average price of $181.33 and a 200-day moving average price of $170.23. The stock has a market capitalization of $135.59 billion, a PE ratio of 16.93 and a beta of 1.36. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10. Amgen also was the target of unusually large options trading activity on Thursday. Stock traders purchased 9,350 put options on the company. This represents an increase of 239% compared to the average daily volume of 2,758 put options.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.84 EPS. Equities analysts anticipate that Amgen Inc. will post $12.58 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were given a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a yield of 2.48%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s dividend payout ratio is 41.93%.

COPYRIGHT VIOLATION NOTICE: “Amgen Inc. (AMGN) Shares Sold by Boyd Watterson Asset Management LLC OH” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/amgen-inc-amgn-shares-sold-by-boyd-watterson-asset-management-llc-oh/1615891.html.

A number of brokerages have recently commented on AMGN. BMO Capital Markets lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price objective for the company. in a research report on Friday, July 21st. They noted that the move was a valuation call. Credit Suisse Group reaffirmed a “neutral” rating and set a $186.00 price objective (up previously from $177.00) on shares of Amgen in a research report on Friday, September 29th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $203.00 price objective on shares of Amgen in a research report on Thursday, September 7th. Leerink Swann reaffirmed a “market perform” rating and set a $161.00 price objective on shares of Amgen in a research report on Thursday, June 22nd. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $196.00 price objective (up previously from $189.00) on shares of Amgen in a research report on Friday. Ten analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. Amgen presently has a consensus rating of “Buy” and an average price target of $189.99.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.